Italian Researchers Develop Hybrid Molecule to Help Immune System Destroy Lung Cancer Cells
A collaborative research effort in Italy has led to the development of a new hybrid molecule designed to enhance the immune system’s ability to recognize and eliminate lung cancer cells. The study, published in the oncology journal Cancer Communications, represents a potential step forward in treating lung cancer, which remains one of the leading causes of death globally.
The innovation centers on a “hybrid” molecule that operates on two distinct fronts to overcome the defenses of malignant cells. According to the research, the molecule first blocks a specific protein that cancer cells typically use as a mechanism to evade the body’s anti-tumor immune response. By neutralizing this protein, the molecule strips away the cancer cells’ primary means of hiding from the immune system.
Simultaneously, the molecule employs a “Trojan horse” strategy. It utilizes that same protein to facilitate the selective internalization of a compound that specifically targets the energy production centers—the “powerhouses”—of the cancer cells. By disrupting and weakening this high energy activity, the molecule renders the cancer cells more vulnerable to attack and destruction by the immune system, effectively halting their growth.
A critical aspect of this discovery is its selectivity. The study coordinators noted that the most significant finding was the molecule’s ability to selectively eliminate cancer cells while maintaining a limited impact on healthy cells. This selectivity is possible because healthy cells have significantly lower energy demands and activity compared to the “greedy” energy requirements of cancerous cells.
The research was a joint effort involving the University of Naples Federico II, the University of Salerno, and the CNR of Milan. The study was coordinated by Daniela Arosio, Luciana Marinelli, and Francesco Sabbatino. In laboratory tests, the new molecule has demonstrated both good efficacy and high selectivity.
This development underscores the importance of targeted immunotherapy in oncology. By combining immune-evasion blocking with metabolic disruption, this hybrid approach could provide a more precise way to weaken tumors without damaging surrounding healthy tissue.
